Growth Opportunities and Trends in the Respiratory Disease Vaccine Market: Key Insights for 2025-2034
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How has the respiratory disease vaccine market grown in recent years?
The respiratory disease vaccine market has experienced slight growth in recent years and is projected to increase from $69.99 billion in 2024 to $70.9 billion in 2025 at a CAGR of 1.3%. This growth has been driven by the rising prevalence of respiratory diseases, increased public vaccination awareness, public health initiatives, and the demand for more effective and tolerable vaccines.
How is the respiratory disease vaccine market size expected to evolve during the forecast period?
The respiratory disease vaccine market is expected to grow steadily, reaching $79.16 billion by 2029, with a CAGR of 2.8%. Market expansion is supported by an aging population, rising healthcare spending, vaccine investments, and pandemic preparedness initiatives. Trends include innovative vaccine development, collaborative research, technological advancements, and accelerated drug approvals.
Get your respiratory disease vaccine market report here!
https://www.thebusinessresearchcompany.com/report/respiratory-disease-vaccine-global-market-report
Which key drivers are propelling the respiratory disease vaccine market’s growth?
The escalation in tuberculosis cases is projected to stimulate the growth of the respiratory disease vaccine market. Tuberculosis is a respiratory infection caused by Mycobacterium tuberculosis, primarily affecting the lungs and potentially other organs, leading to a variety of complications. The surge in tuberculosis cases can speed up the development and distribution of vaccines for respiratory diseases to diminish tuberculosis spread. By way of illustration, data from the Centers for Disease Control and Prevention, a US government agency, reported in November 2023 that there were 8,331 cases of TB in the United States in 2022, signifying a 5.9% increase in case numbers compared to 2021. The incidence rate grew to 2.5 cases per 100,000 individuals, showing a rise of 5.5% from the preceding year. Therefore, the escalating occurrence of tuberculosis is anticipated to be a driving force for the respiratory disease vaccine market. The rising prevalence of smoking is anticipated to fuel the expansion of the respiratory disease vaccine market. Smoking, which involves inhaling and exhaling the smoke produced from burning tobacco or similar products, provokes numerous health complications such as tracheitis, heart diseases, stroke, and cancer. Immunizations against specific respiratory illnesses can offer protection for smoking individuals to a certain extent. For instance, Statistics Canada, a Canadian government agency reported in July 2022 that the production of cigarettes saw a growth of 5.8% compared to June 2021. Additionally, there was a 1.3% increase in the total count of sold cigarettes from May 2022, with sales hitting 1.4 billion in June 2022. Hence, the augmenting prevalence of smoking is contributing to the expansion of the respiratory disease vaccine market.
What are the market segments in the respiratory disease vaccine industry?
The respiratory disease vaccine market covered in this report is segmented –
1) By Type: Viral Vaccine, Bacterial Vaccine, Combination Vaccine
2) By Infection: COVID-19, Influenza, Respiratory Syncytial Virus (RSV), Pneumonia, Other Infections
3) By Age: Infant, Adolescent, Adult
4) By End-User: Clinic, Hospital, Other End-Users
Subsegments:
1) By Viral Vaccine: Influenza Vaccine, Respiratory Syncytial Virus (RSV) Vaccine, Coronavirus Vaccine
2) By Bacterial Vaccine: Pneumococcal Vaccine, Haemophilus Influenzae Type B (Hib) Vaccine, Pertussis Vaccine
3) By Combination Vaccine: DTaP With Hib And IPV, Pneumococcal Conjugate Vaccine With Influenza Vaccine, MMRV
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12924&type=smp
Which leading companies are shaping the growth of the respiratory disease vaccine market?
Major companies operating in the respiratory disease vaccine market are Pfizer Inc., Johnson & Johnson Ltd., Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, GlaxoSmithKline PLC, Sinovac Biotech Co. Ltd., Moderna Inc., BioNTech SE, CSL Limited, Daiichi Sankyo Company Limited, Mitsubishi Tanabe Pharma Corporation, Novavax Inc., Emergent BioSolutions Inc., Seqirus, Bio Farma, Dynavax Technologies Corporation, Hualan Biological Bacterin Co. Ltd., Serum Institute of India Pvt. Ltd., Bavarian Nordic A/S, Valneva SE, Biological E. Limited, CanSino Biologics Inc., Bharat Biotech International Limited, Medicago Inc., CureVac N.V., Incepta Vaccine Ltd., Inovio Pharmaceuticals Inc., Ology Bioservices, VBI Vaccines Inc.
What key trends are currently impacting the respiratory disease vaccine market’s development?
Top companies engaged in the respiratory disease vaccine market are focusing on the development of cutting-edge products to increase their efficiency and offer better solutions for the prevention and treatment of respiratory disease infections. For instance, in May 2023, Pfizer Inc., a pharmaceutical firm based in the United States, gained approval from the Food and Drug Administration (FDA) for ABRYSVO (Respiratory Syncytial Virus Vaccine), a bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine. This was designed to prevent lower respiratory tract disease caused by the respiratory syncytial virus in people aged 60 years and older. ABRYSVO, a vaccine without adjuvant, consists of a couple of preF proteins specifically designed to strengthen immunity to RSV A and B types. Clinical evidence confirms its safety and effectiveness.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12924
Which geographic areas are influencing the growth of the respiratory disease vaccine market?
Asia-Pacific was the largest region in the respiratory disease vaccine market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in respiratory diseases vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Browse Through More Similar Reports By The Business Research Company:
Respiratory Devices And Equipment (Therapeutic) Global Market Report 2024
Respiratory Devices And Equipment (Diagnostic) Global Market Report 2024
Respiratory Disposables Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/respiratory-disposables-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
